In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Featured Stories

Will Advanced Technology Simulations Lead To More And Better Drugs? Start-Up Schrodinger Says It Can

Schrodinger LLC is a leading player in the emerging high-stakes field of computational chemical simulation software to boost the quality and productivity of drug discovery and lead generation. Its business model relies heavily on validating theoretical concepts of science and engineering in real-world settings through partnerships with a blue-chip list of pharma and biotech companies.

Digital Health Innovation BioPharmaceutical

Strategic Fingers In Digital Health Pies

Investors in digital health are a different breed. They invest less than life science investors, and they expect (and receive) more rapid returns. What's more, the corporate, strategic investment funds are not simply the venture arms of big pharma and medtech; health insurers and the tech firms are in there, too. And, guess what – they have entirely different agendas.

Digital Health Financing Healthcare Systems

Digital's Big Moment Has Arrived Say CEOs At Medtech Europe Panel

The waiting is over and digital technologies are being adopted at pace, according to a CEOs Unfiltered panel at MedTech Europe's 2018 Forum. Connected care is at the top of the priority list, say Siemens Healthineers' Bernd Montag, AdvaMed Chairman/CVRx President and CEO Nadim Yared and former bioMerieux President and CEO Jean-Luc Bélingard, although it's not the only pressing issue on the bill.

Leadership Digital Health Medical Device

Digital Health - An Infographic

The world of health care has become much connected thanks to the venture capital that has already poured into health-related social media structures and the Internet-Of-Things. People are connected to sensors, devices are connected to phones, and patients are connected to physicians. The latecomers pharmaceutical and medtech firms –  can now plug in to this partly-formed network both through direct investment and their strategic venture funds.

Digital Health Market Intelligence Financing

2018 Outlook

Insights from In Vivo on what to expect in the coming year

Recent Tweets from In Vivo

Growth Explore this Topic

Set Alert for Growth

Latest From Growth

How Healthy Is Your Growth Strategy? Five Principles To Fight Complexity In Today’s Medtech And Biopharma Enterprise

Top performers in today’s health care market are transforming their growth strategies. They excel at category leadership, cost reduction and customer-focused innovation. Complexity – in strategy, portfolios, operations, organizations and people – is a little-noticed impediment to achieving margin-busting growth, on target and on time.

Business Strategies Growth

Mid-level Player In A Big-league Market; Merck KGAA Plots A US Strategy Beyond Bavencio

Mid-size biopharma companies are industry’s “stealth” players, occupying a small but important space in the race for new innovative therapies. In Vivo explores the growth prospects of one of the more prominent entrants in this space, Merck KGAA, whose fortunes depend heavily on building a strong oncology and immunology franchise in the US market.

BioPharmaceutical Growth

Biopharma R&D Productivity And Growth 2017: Big Pharma Closes The Gap

Catenion updates its annual list of the year's top pharma R&D performers. R&D productivity declined for the first time since 2014. Mid pharmas continue to dominate the top 10, but big pharmas are making inroads.

BioPharmaceutical Research and Development Strategies

Innovation Explore this Topic

Set Alert for Innovation

Latest From Innovation

Mesoblast’s Late-Stage Pipeline Could Be Game Changing: Are Investors Paying Attention?

Mesenchymal cell specialist Mesoblast came back from a near-death experience in 2016 when Teva returned a key asset. But recent success in a Phase III trial in acute GVHD has brought it some attention. Now it needs to repeat the achievement in advanced heart failure and find a partner for its burgeoning pipeline.

Regenerative Medicine Research & Development

Abuse-Deterrent Formulations of Opioid Analgesics Face Uphill Battle

Commitment by biopharma to the development of new abuse-deterrent formulations of opioid pain medications is hampered by unresolved issues of development complexity; cost and willingness of payers to reimburse; and regulatory requirements for extensive, industry-financed postmarketing studies. Less addictive alternatives to existing opioid drugs that effectively address the overdose challenge where it’s particularly lethal – through injecting and inhaling rather than oral formulation abuse – are unlikely to enter widespread use anytime soon.

Drug Approval Standards Research & Development

Giant LEAPS For Mankind: Bayer's Malik On Breaking The Mold In R&D

As new scientific breakthroughs are shaking the foundations of pharma and biotech R&D, In Vivo sat down with Bayer's Kemal Malik to hear how the German big pharma is responding to the challenges with its ground-breaking LEAPS program.

Financing Regenerative Medicine

Leadership Explore this Topic

Set Alert for Leadership

Latest From Leadership

MedTech Europe's Brexit Challenge: Don't Forget The Kid In The EU Divorce

 The UK continues to press for favorable trading and regulatory conditions with the EU in its Brexit planning. But EU negotiators seem likely to play it by the book, with no favors shown. The medtech industry watched as the EU withdrawal agreement was approved by the EU27 at the March 2018 Euro Summit. Some weeks prior to that, MedTech Europe chief executive Serge Bernasconi told In Vivo of his fears for EU medtech if the industry was too slow in preparing for UK withdrawal. 

EU Brexit

State Of Pharma R&D: Ex-Takeda’s Yamada Takes The Long View

Industry veteran Tadataka Yamada draws on his multidisciplinary background for perspectives on what’s new – and what isn’t – in a field where every researcher has at some point experienced the same teachable moment:  when you strive to make a medicine, so many things can go wrong.

Research & Development Clinical Trials

Biopharma In The Digital Age: Critical Success Factors

It seems only a matter of time that the leaders of established biopharma will need to redefine core functions such as research, manufacturing and marketing around a new vision.

Digital Health Leadership

Market Access Explore this Topic

Set Alert for Market Access

Latest From Market Access

Winners Are Beginning To Emerge In Digital Health – But Without Planning Medtechs Risk Missing The Boat

The leading medtechs are starting to develop models for providers that show how to implement successful digital strategies, a trend that is serving to put pressure on companies that are yet to make a commitment, says ZS Associates' Pete Masloski.


Market Access Digital Health

Doubling Pharma Value With Data Science

A once-in-a-generation opportunity has opened to digitally redesign a core part of the biopharma business. Capturing the opportunity requires vision and leadership; it’s not about the technology.

Digital Health Business Strategies

The Tailor Will See You Now – J&J's EMEA VP Explains Total Care Partnership For Hospital Systems

Johnson & Johnson's global CareAdvantage system, a tool to help hospital systems deliver quality care efficiently and affordably, was launched in spring 2017. Almost a year into the initiative, Hugo Breda, the group’s EMEA vice president, explains the role that J&J plays as it brings its unique care provision concept to clients.

Business Strategies Market Access

Market Intelligence Explore this Topic

Set Alert for Market Intelligence

Latest From Market Intelligence

Deals Shaping The Medical Industry April 2018

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in March 2018. 

Deals BioPharmaceutical

Deals In Depth: February 2018

Bristol-Myers Squibb and Nektar cemented a $3.6 billion immuno-oncology combination deal centered on an earlier trial collaboration. Roche acquired Flatiron Health and its software capabilities in mining electronic medical records for $1.9 billion. Moderna, Procept BioRobotics, and HeartFlow each raised big late-stage rounds.
Deals Market Intelligence

Big Pharma Presence In Gene Therapy Dealmaking Validates Technology

For several years, smaller biotechs have been advancing gene therapies and delivery technology. Big Pharma companies have increasingly been becoming involved through deal-making, and are ready to take gene therapy to the next level.
Regenerative Medicine Deals